Acorda Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 29.68 million compared to USD 31.05 million a year ago. Net loss was USD 9.38 million compared to USD 46.68 million a year ago. Basic loss per share from continuing operations was USD 7.55 compared to USD 54.01 a year ago. Diluted loss per share from continuing operations was USD 7.55 compared to USD 54.01 a year ago.
For the six months, revenue was USD 51.93 million compared to USD 53.59 million a year ago. Net loss was USD 26.21 million compared to USD 71.21 million a year ago. Basic loss per share from continuing operations was USD 21.1 compared to USD 97.33 a year ago. Diluted loss per share from continuing operations was USD 21.1 compared to USD 97.33 a year ago.